News >

Guadecitabine Highly Active in AML

Jason Harris
Published: Thursday, Nov 02, 2017

Hagop M. Kantarjian, MD

Hagop M. Kantarjian, MD
More than half of elderly, treatment-naïve patients with acute myeloid leukemia (AML) assigned to treatment with guadecitabine (SGI-110) had a composite complete response irrespective of dosage or schedule, according to results from a phase 1/2 study published in The Lancet Oncology.1

Hagop M. Kantarjian, MD, with MD Anderson Cancer Center and colleagues recruited 107 treatment-naïve patients at 14 medical centers in the United States for this multicenter, randomized, open-label study. From August 2012 to September 2014, patients were randomly assigned to 60 mg/m2 (n = 26) or 90 mg/m2 (n = 28) of guadecitabine on days 1 to 5 (5-day schedule) of a 28-day cycle, or 60 mg/m2 (n = 53) on a 10-day schedule, also in a 28-day cycle. Median age was 77 years and median follow-up was 953 days.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication